This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
SNCE Overzicht aandelen
Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 1 meer risico
Science 37 Holdings, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$5.75 |
| 52 Week Hoogtepunt | US$12.96 |
| 52 Week Laag | US$3.73 |
| Bèta | 0.57 |
| 11 maand verandering | 1.23% |
| 3 maanden verandering | 30.39% |
| 1 Jaar Verandering | 30.86% |
| 33 jaar verandering | -97.22% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -97.14% |
Recent nieuws en updates
Recent updates
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks
Dec 18
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)
Apr 17Science 37, Syapse team for faster patient enrollment in cancer trials
Aug 18Science 37 reports Q2 mixed earnings; narrows FY22 guidance
Aug 11Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans
Apr 11Science 37: Pioneering Decentralized Clinical Trials
Jan 02We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth
Nov 04Rendement voor aandeelhouders
| SNCE | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 0.3% | 2.2% | -1.6% |
| 1Y | 30.9% | 17.9% | 30.8% |
Rendement versus industrie: SNCE exceeded the US Life Sciences industry which returned 9% over the past year.
Rendement versus markt: SNCE matched the US Market which returned 31% over the past year.
Prijsvolatiliteit
| SNCE volatility | |
|---|---|
| SNCE Average Weekly Movement | 15.6% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: SNCE's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: SNCE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2014 | 460 | Dave Coman | www.science37.com |
Science 37 Holdings, Inc. Samenvatting
| SNCE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$34.67m |
| Inkomsten(TTM) | -US$124.65m |
| Inkomsten(TTM) | US$60.26m |
0.6x
P/S-verhouding-0.3x
Koers/WinstverhoudingIs SNCE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SNCE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$60.26m |
| Kosten van inkomsten | US$38.14m |
| Brutowinst | US$22.12m |
| Overige uitgaven | US$146.77m |
| Inkomsten | -US$124.65m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -20.67 |
| Brutomarge | 36.71% |
| Nettowinstmarge | -206.85% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde SNCE op de lange termijn?
Bekijk historische prestaties en vergelijking